Richard P. Baum

4 ta ish

Zentralklinik Bad Berka

1. Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

   Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin +32

   MaqolaOAOchiq kirish20173 iqtibos

   ABIABI:AkademIndex/2026.other.011754

2. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

   Richard P. Baum, Christiane Schuchardt, Aviral Singh +12

   Maqola20213 iqtibos

   ABIABI:AkademIndex/2026.other.340321

3. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS

   Frank Rösch, Richard P. Baum

   Maqola20112 iqtibos

   ABIABI:AkademIndex/2026.other.059022

4. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

   Clemens Kratochwil, Wolfgang P. Fendler, Matthias Eiber +22

   Maqola20192 iqtibos

   ABIABI:AkademIndex/2026.other.287817